mru buy pipelin track head near-
runway
messag mru report earn line expect earli
pipelin bispecif antibodi remain track head near-term data readout
acut myeloid leukemia aml initi safeti data
solid tumor ye updat result patient
fusion ye recent follow-on offer provid potenti cash runway
maintain buy pt continu believ mru differenti
bispecif antibodi technolog platform allow rapid product candid screen
lead optim
buy rate mru pt pleas see next-gen antibodi platform
initi note main valu driver stock lie earli pipelin consist
 bispecif
 egfr view potenti differenti target acut myeloid
leukemia aml limit express profil rel commonly-target
receptor combin mru lower-affin arm theoret
reduc severity/frequ cytokin releas syndrom believ
offer differenti profil rel t-cell engag aml therapi
current model po remain cautiou given modest histor
singl agent efficaci observ date histor difficulti antibodies/
bispecif competit sever agent link believ
valu current stock asset beyond repres potenti upsid
updat zenocutuzumab data gene fusion
patient expect ye zenocutuzumab recent read initi proof-of-concept
data nci-aacr-eortc tripl meet link includ orr among
evalu patient code ligand tyrosin
kinas fusion activ oncogen
previous highlight see mru earn note gene fusion may
present test solid cancer sampl link includ
nsclc pancreat cancer link
guidanc maintain dose escal result
recal design lower-affin arm aml-select
target see next-gen antibodi initi potenti enhanc safeti
profil engag via reduc cytokin releas syndrom theoret spare
erythrocyt platelet progenitor cell mru amend phase dose escal trial
juli link allow explor higher dose result guidanc
push note preliminari anti-tumor activ
observ dose escal
mru continu expect initi clinic data egfr ye
line prior guidanc emerg data phase trial includ
safeti inform around recommend phase dose expect end
accord mru management plan provid guidanc program
phase dose escal expans trial asset
partner progress plan recal mru develop
part collabor potenti develop commerci
antibodi gener mru biclon platform
updat estim account result mru end quarter
cash cash equival invest includ gross proce
page analyst certif import disclosur
novemb follow-on offer modestli adjust oper expens
light result maintain buy pt
page analyst certif import disclosur
valuat risk
arriv price target mru use discount cash flow analysi
use wacc consist clinical-stag
biotech compani cover proof-of-concept data well termin
growth rate risk includ regulatori commerci setback potenti
emerg new competitor lower product sale expect
page analyst certif import disclosur
total cost expens
interest incom net
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
